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A B S T R A C T
Breast carinoma falls into a heterogeneous group of diseases which can be determined by various prognostic factors.
The identification of clinical and histopathologic factors is of great value in predicting the progression of tumor growth
and survival outcome. Due to a high degree of cell proliferation in breast tumors and high genetic instability of these tu-
mors, as a consequence of defective DNA repair mechanisms, chemotherapy as a treatment option often renders very suc-
cessful results. During our scientific study of the expression of genes responsible for mismatch repair of DNA in cells of
invasive ductal carcinoma we also compared the patient survival rate with the major prognostic factors. This study in-
cluded 108 patients who were surgically treated for invasive breast cancer at the Department of Plastic, Reconstructive
and Aesthetic Surgery, University Hospital »Dubrava«. The overall survival rate was compared to factors such as initial
tumor stage, regional lymph node involvement and distant metastasis. The overall five year survival rate of our patients
was 78,7%. Patients without the presence of distant metastasis, a lower rate of local lymph node involvement and a lower
tumor stage statistically had a longer overall survival period. It is important that physicians recognize the various cli-
nico-pathohistological factors in patients with breast carcinoma. This study confirms that this prognostic factors deter-
mine the type of treatment required and most important, the patient overall survival period.
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Introduction
Breast carcinoma is a leading cause of cancer related
deaths among women worldwide. Every ninth woman at
some point in her lifetime will develop breast carcinoma.
Its multifactorial etiology means that there are a wide
range of exogenous and endogenous factors which in-
crease the risk of developing breast carcinoma. Despite
numerous options available to the physician for the diag-
nosis and treatment of breast carcinoma, this disease
still remains the leading cause of death in women aged 35
to 59. Women in Croatia are at a high risk of developing
breast carcinoma, with an increased number of young fe-
males developing aggressive subtypes when compared to
other western countries1–6.
Breast carcinoma has been attributed to abnormal ge-
netic and epigenetic changes specifically occurring in the
BRCA1 and BCRA2 genes2,7. There are more than 40
genes that have been shown to be inactivated in breast
carcinoma cells. These include the genes responsible for
cycle regulation, cell signalization, cell adhesion and
DNA repair8. DNA polymerase is responsible for base
pair integration during replication and should errors oc-
cur, including incorrectly matched base pairs, they are
usually repaired by the presence of the mismatch repair
system (MMR). Lowered MMR protein activity can lead
to a mutated phenotype with an increased degree of
spontaneous mutations as the result. It has been ob-
served in breast carcinoma that the MSH2 gene, respon-
sible for recognizing any mismatched base pairs, can be
mutated into many variants9,10.
459
Received for publication May 2, 2013
	
	
%2
	&
 
!
"
	
The majority of authors agree that the successful
treatment of breast carcinoma is dependant on early di-
agnosis5,9,11,12.
This research was conducted with the aim to compare
the clinical and patohistological factors with the overall 5
year survival rate in a population of Croatian women
with invasive ductal breast carcinoma.
Materials and Methods
This research analyzed the clinical and patohisto-
logical factors affecting the 5 year survival rate in Cro-
atian women with invasive ductal breast carcinoma. 108
female patients who were operated at our Department
between 1999 and 2002 were included in this study. The
required data was collected through the available docu-
mentation which included patient history charts, clinical
charts, operative charts, anesthisiological charts and per-
sonal interviews. Survival and prognostic data was also
taken from the Croatian Epidemiological registry of can-
cer patients and deaths due to malignant diseases. It was
determined that the majority of the sample group, 70 pa-
tients (77.8%) were in the first two stages of disease clas-
sification. 34 patients (37.8%) were in the first stage, 36
(40%) in the second, 16 (17.8%) in the third and only 4
(4.44%) patients in the fourth. Initially, all of our pa-
tients were surgically treated which included axillary
lymph node resection as well. Afterward, standardized
type of adjuvant therapy was indicated and initiated. In
all of our patients, information regarding tumor size,
TNM stage, age, menopausal status, type of adjuvant
therapy used, lymph node status, residual disease, length
of disease remission and overall survival rates were col-
lected. Only patients with complete statistical informa-
tion were included in the study.
The analysis of variance between quantitative vari-
ables such as the degree of differentiation with clinical
and laboratory standards was compared using the ANO-
VA method while qualitative variables were analyzed us-
ing the c²-test.
The main ethical committee at the Clinical Hospital
Dubrava in Zagreb, Croatia approved the methods and
research conducted.
The data regarding the overall survival rate of our pa-
tients was collected and was compared to prognostic fac-
tors such as initial tumor stage, regional lymph node in-
volvement and distant metastasis. With the high risk of
Croatian women developing aggressive subtypes of breast
carcinoma the aim of our research was to determine any
significance between the overall survival rate and those
prognostic factors.
Results
In our group of patients the average age at diagnosis
was 56.1 years with 14 patients (15.6%) having a positive
family history of breast carcinoma when compared to 76
patients (84.4%) who did not. All of the patients were
classified using the international TNM classification sys-
tem; tumors up to 2 cm were found in 53 (58.9%) pa-
tients, tumors between 2–5 cm in 35 (38.9%) patients,
and tumors larger than 5 cm in 2 patients (2.2%). It was
found that the majority of our patients had carcinomas
that were located in the left breast 59 (65.6%) compared
with 31 (34.4%) patients who had a tumor located in the
right. Lymphovascular involvement was found in only 10
patients (11.1%), compared with 88,9% of patients who
lacked lymphovascular invasion at the time of initial di-
agnosis. While the majority of the patients (54.4%) did
not have lymph node involvement at the time of diagno-
sis, lymph node positive cases were found in 24 patients
(26.7%) who had between 1–3 positive nodes (N1 stage),
10 patients (11.1%) who had between 3–10 positive nodes
(N2 stage). More than 10 positive nodes (N3 stage) were
found in only 7 patients (7.8%). It was observed that the
presence of distant metastases was found in 4 patients
(4.4%).
All of the disease positive patients with breast carci-
noma were treated with surgery, adjuvant cytostatic,
hormonal and/or radiotherapy according to the stage of
the disease and steroid receptor status. Out of the entire
sample group, only 8 (8.9%) of our patients relapsed with
disease.
In our experimental group it was determined that the
overall 5 year survival rate was 78,7%. The follow up pe-
riod was recorded in months, starting at the time of ini-
tial diagnosis until the death of the patient or final clini-
cal check up. Figure 1 presents the overall survival rates
in our sample group.
The analysis of the number of patients and diseases
free survival period is represented in Figure 2. The 5
year disease free period in our patients was 75.4% and
was recorded in months; beginning at the time of initial
diagnosis.
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Fig. 1. Overall survival rate (in months) in Croatian women with
ductal breast carcinoma.
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Statistically it was proven that the overall surviuval
rate of our patients was realted to the involvement of re-
gional lymphnode (p=0.018), presence of distant metas-
tasis (p=0.036) and tumor stage (p=0.001). (Table 1)
When comparing tumor stage and overall survival
rates of our patients it was statistically proven that a
large variation in survival rates exists between the vari-
ous tumor stages (p=0.001). Overall survival rates was
90% in the first stage, while only 25% in the fourth stage.
It is important to emphisize that the majority of patients
with stage 4 disease die within 20 months of initial diag-
nosis (Figure 3). It was observed a statistically signifi-
cant correlation to overall survival rates and the presen-
ce of local lymph node involvement (p=0.018). (Figure 4)
There was a statistically significant correlation to
overall survival rates and the presence of distant metas-
tasis at the initial time of diagnosis (p=0.036). It was
concluded that patients with the presence of distant me-
tastasis have a significantly lower survival rate when
compared to patients without any distant metastasis
(Figure 5).
In the sample group, the overall 5 year survival rate
was 78.7%, with 75% of these patients without any re-
lapse of disease. It has been found that the overall sur-
vival rate is statistically related to the involvement of
axillary lymph nodes (p=0.018), the presence of distant
metastasis (p=0.036) and the stage of disease (p=0.001).
Discussion
Breast carcinoma is one of the most frequent carcino-
mas found in women world wide. This is also the case for
the Croatian population. There have been several clinical
and patohistological factors that have been recognized
and are used as prognostic determinants in breast cancer
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Fig. 2. Disease free survival period in months.
TABLE 1
ANALYSIS OF CLINICAL AND PATHOHISTOLOGICAL FACTORS
AND THE OVERALL SURVIVAL RATE OF CROATIAN WOMEN
WITH INVASIVE DUCTAL BREAST CARCINOMA
Observed Factor Beta* c2 p
Tumor Stage (I, II, III, IV) 0,726 10,985 0,001
Nodal involvement (0,1,2,3) 0,429 5,078 0,018
Distant Metastasis (0,1) 1,393 3,274 0,036
* Regression coefficient. Negative results signify an inversly
proportional relationship
Fig. 3. Tumor stage and the overall survival rate of Croatian wo-
men with invasive ductal breast carcinoma. (Group 1,2,3,4) re-
lates to the subsequent stage of disease at the time of initial diag-
nosis.
Fig. 4. Stage of local lymph node involvement and the overall pa-
tient survival rate. (Group 1,2,3,4) relates to the degree of regio-
nal lymph node involvement.
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patients including tumor size, histologic type, tumor
grade, lymphovascular invasion, and hormone receptor
status13–16. The relationship between microscopic grade
and the degree of tumor malignancy was observed by von
Hansemann towards the end of the 19th century17. Pres-
ently, the Nottingham method18,19 is most often used in
order to define the histological grade of a tumor. Litera-
ture states that patients with well differentiated tumors
have a 10 year survival rate of up to 85% after diagnosis
in contrast to patients who have poorly differentiated tu-
mors and a 10 year survival rate of about 45%. Bloom20,
Elston and Le Dousal21 found that there was a direct cor-
relation between the tumor grade and the overall sur-
vival rate. It has been shown that the tumor stage at the
initial point of diagnosis is a strong predictor of breast
cancer survival rate22,23. It was observed by Laurens
Holmes JR et al. that there is a monotonic increase in
breast cancer mortality with advancing tumor stage at
the time of initial diagnosis24. If primary breast cancer is
diagnosed when tumors are small (<1 cm) and without
any presence of metastasis to regional lymph nodes, the
overall 5-year survival rate has been shown to be to ex-
ceed 90%. This emphasizes the importance of early dis-
ease detection. Unfortunately, larger (>5 cm) breast
cancers with regional nodal metastasis have a 5-year sur-
vival which has been found to be as low as 40%. 24740 pa-
tients were analyzed by Carter et al who found that their
patients who had a tumor size smaller than 1 cm had a
99% 5 year survival period while patients with a tumor
between 1 and 3 cm, had only a 89% 5 year survival rate25.
Biological hormonal receptor status has been obser-
ved to be an important factor in the determination of
therapy success. Kyoung-Mu Lee et al.26 in 544 patients
determined that patients who were without tumor based
hormone receptors, overall had a worse prognosis and
that the presence of hormone receptors is an important
factor when determining the type of therapy required.
Similar findings by Colditz27 were found. A study con-
ducted by Sondes Karray-Chouayekh28 showed that
estrogen receptor negative carcinomas had a higher ma-
lignant degree. Our results also correlate with Layfield29,
Braum30 and Scawn31 who displayed a relationship with
positive hormone receptors and a lower tumor grade
with a longer survival rate.
Fisher B and Carter CL concluded that the presence
of axillary lymph node metastasis is the most important
prognostic factor for predicting breast cancer patient
survival32. Lymph node involvement has also been found
to be an important prognostic factor since patients with
lymph node metastasis had a lower overall survival rate
which concurs with multiple foreign studies. One such
study has found that patients after 9 years who didnt
have lymph node metastasis had a 74% chance of sur-
vival as compared with 47% who had metastasis. There-
fore, it is important for the physician to recognize these
findings as one of the most important prognostic factors
for their patients25,33,34. Our research concluded that pa-
tients who were axillary lymph node negative, had a sur-
vival rate of 81.1% as opposed to 65% in node positive pa-
tients.
Perhaps one of the most important factors influenc-
ing the overall survival rate of patients with breast can-
cer is the presence of distant metastasis as this factor
represents the main cause of death in women with breast
cancer35,36. Lamerato L et al. in their retrospective cohort
study showed that the median time to all-cause mortality
is significantly longer in women with loco-regional recur-
rence than in those who presented with distant metasta-
sis (6.4 versus 3.4 years, respectively)37. Similar research
conducted by Lê MG et al. found that the 10-year sur-
vival rate in women with local recurrence was 56% when
compared with 9% in those with distant disease38.
In the Early Breast Cancer Trialists’ Collaborative
Group meta-analysis of local therapy (39), it was found
that for every four local recurrences that were prevented
at 5 years, there was about one less death from breast
cancer at 15 years. This finding suggests that in about
25% of local recurrences, the cancer cells in the recurrent
tumor have acquired the ability or have the opportunity
to spread distantly. This subsequently leads to an in-
creased risk of death from metastatic disease. An in-
crease in distant metastases after the diagnosis of local
recurrence has been documented in both the breast-con-
servation and post-mastectomy patients39–42.
The majority of authors agree that the successful
treatment of breast carcinoma is dependent on early
diagnosis5,8,11,12. Tumors smaller than 1 cm in the major-
ity of cases are considered curable. Many authors exist
who believe that breast carcinoma is a systemic disease 43
and support of this theory can be seen with the variable
biological behavior found in breast cancer cells. This
holds especially true for the invasive ductal carcinoma
which is also the most frequently seen. Due to this vari-
ability there is a great degree of difficulty when attempt-
ing to treat this disease. As a result and due to the uncer-
tainty and behavior of this common disease, invasive
ductal carcinoma is therefore the focus of numerous
studies44,45.
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Fig. 5. The presence of distant metastasis and the overall sur-
vival period (in months).
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With the development of new medications such as
cytostatics, the treatment of breast cancer is becoming
more successful; although there are still numerous asso-
ciated side effects46–49. It is imperative that the physician
recognizes the wide range of treatment options and which
patients will have the greatest benefit from pharmaco-
logic therapy. It is also important that the physician max-
imizes the effort to reduce the possible side effects as
much as possible 50,51. A certain degree of disease pro-
gression can be foreseen by observing the previously
known signs and symptoms at the time of initial diagno-
sis; this includes tumor size, axillary lymph node involve-
ment and the hormonal receptor status52,53. These fac-
tors directly influence the therapy options and the right
choice of breast reconstruction method54–57.
The majority of medical literature states the impor-
tance of histological tumor grading since this is an im-
portant prognostic factor. It also influences and deter-
mines for the need for adjuvant therapy in patients
without lymph node involvement who initially present
with a smaller tumor25.
Lymph node involvement has been shown to be an im-
portant prognostic factor since patients with lymph node
metastasis tend to have a lower survival rate. Our re-
search showed that a relationship exists between lymph
node involvement and overall survival rate (p=0.018).
This discussion signifies the importance for physi-
cians to recognize the various clinico-pathohistological
signs and symptoms in patients with breast carcinoma.
These factors influence the type of treatment required
and most importantly, the overall prognosis of the pa-
tient.
Conclusion
In patients who did not have distant metastasis, had a
lower rate of local lymph node involvement and had a
lower initial tumor stage statistically had a longer overall
survival period.
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KLINI^KI I PATOHISTOLO[KI ^IMBENICI KOJI UTJE^U NA PETOGODI[NJU STOPU
PRE@IVLJAVANJA U POPULACIJI @ENA S INVAZIVNIM DUKTALNIM KARCINOMOM DOJKE
U HRVATSKOJ
S A @ E T A K
Karcinom dojke spada u heterogenu grupu bolesti na koju utje~u mnogi prognosti~ki ~imbenici. Identifikacija kli-
ni~kih i patohistolo{kih ~imbenika je od velike va`nosti u predvi|anju progresije tumorskog rasta i stope pre`ivljena
pacijentica. Zbog visokog stupnja proliferacije stanica tumora dojke i genetske nestabilnosti tih tumora, kao posljedice
nepravilnog mehanizma za popravak o{te}enja DNA, kemoterapija kao terapijska opcija daje vrlo dobre rezultate. U
sklopu istra`ivanja ekspresije gena odgovornih za popravak krivo sparenih baza u molekuli DNA u stanicama invaziv-
nog duktalni karcinoma, provedena je i usporedba stope pre`ivljenja i glavnih prognosti~kih ~imbenika. U ovo istra`i-
vanje uklju~eno je 108 pacijentica koje su kirur{ki lije~ene zbog invazivnog karcinoma dojke na Klinici za plasti~nu,
rekonstruktivnu i estetsku kirurgiju, KB »Dubrava«. Ukupna stopa pre`ivljenja promatrana je u odnosu na po~etni
stadij tumora, prisutnost regionalnih metastaza u limfnim ~vorovima i udaljenih metastaza. Ukupna petogodi{nja sto-
pa pre`ivljenja na{ih pacijenata bila je 78,7%. Pacijentice bez prisutnosti udaljenih metastaza, manjim stupnjem zahva-
}enosti limfnih ~vorova i ni`im stadijem tumora statisti~ki su imale bolju stopu pre`ivljenja.. Ova studija potvr|uje da
navedeni prognosti~ki ~imbenici odre|uju na~in lije~enja i najva`nije, utje~u na pre`ivljenje pacijentica.
R. Milanovi} et al.: 5 Year Survival Rate for Invasive Ductal Breast Carcinoma, Coll. Antropol. 37 (2013) 2: 459–464
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